Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind placebo-controlled study of CM326 in chronic rhinosinusitis with nasal polyps
CTR20241156Phase 2Active
- Sponsor
- Keymed Biosciences
- Start
- Jun 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of CM326 in chronic rhinosinusitis with nasal polyps (CRSwNP), sponsored by Keymed Biosciences. Started Jun 2024; status: active.
02
Drugs
CM326
03
Conditions
chronic rhinosinusitis with nasal polyps (CRSwNP)
Beyond the preview
Go deeper on CTR20241156.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20241156.